EnBiotix: Funding, Investors & Team (Sep 2026)
EnBiotix is a product-focused bioengineering company that advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections. Through breakthrough systems and synthetic biology platforms, EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections. These approaches have developed a robust clinical product pipeline addressing a wide range of acute and chronic infections in what is today over a $40 billion market, with the potential to significantly impact the lives of patients, caregivers, and payors worldwide. It was founded in 2012 and is headquartered in Cambridge, Massachusetts.
EnBiotix has raised $14.5M across 2 funding rounds on record, the most recent an undisclosed round of $3.5M announced in Apr 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
EnBiotix Company Profile and Key Stats
Latest funding round on record: Apr 2022.
EnBiotix Funding Rounds
EnBiotix raised $11.0M in a Convertible Note announced in Dec 2021.
4 months later, an undisclosed round of $3.5M was announced in Apr 2022.
EnBiotix Founders and Leadership Team
No contact details are on record for this team yet.
EnBiotix Funding Compared to Other Biotechnology Startups
EnBiotix's latest round of $3.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like EnBiotix in Biotechnology and Cambridge
Companies Similar to EnBiotix
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
EnBiotix Funding FAQs
What does EnBiotix do?
EnBiotix is a product-focused bioengineering company that advances front-line labeled products for chronic, recurrent, and life-threatening pulmonary infections. Through breakthrough systems and synthetic biology platforms, EnBiotix is transforming and revitalizing existing antibiotic classes to combat the global rise of drug-resistant bacterial infections. These approaches have developed a robust clinical product pipeline addressing a wide range of acute and chronic infections in what is today over a $40 billion market, with the potential to significantly impact the lives of patients, caregivers, and payors worldwide. It was founded in 2012 and is headquartered in Cambridge, Massachusetts.
How much funding has EnBiotix raised?
EnBiotix has raised $14.5M across 2 rounds on record. The most recent is an undisclosed round of $3.5M announced in Apr 2022.
When did EnBiotix last raise funding?
EnBiotix's most recent funding round on record is an undisclosed round of $3.5M, announced in Apr 2022.
Who is the CEO of EnBiotix?
Jeffrey Wager is listed as CEO at EnBiotix.
Where is EnBiotix headquartered?
EnBiotix is based in Cambridge, Massachusetts, United States.
How many employees does EnBiotix have?
EnBiotix is in the 1-10 employee band.
How does EnBiotix's funding compare to other Biotechnology startups?
EnBiotix's latest round of $3.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's EnBiotix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for EnBiotix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.